90
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

The FCRL3 −169T>C polymorphism might be associated with some autoantibody presence in patients with SLE in a Polish population

, , , , &
Pages 296-299 | Received 05 Feb 2013, Accepted 24 Mar 2013, Published online: 05 Mar 2014
 

Abstract

Objectives. The Fcrl3 −169T>C (rs7528684) polymorphism has been shown to be a risk factor of various autoimmune diseases, including systemic lupus erythematosus (SLE); however, these results are inconsistent between distinct ethnicities.

Methods. Using PCR-RFLP we studied the distribution of the FCRL3 −169T>C polymorphism in SLE patients (n = 263) and controls (n = 528) in a sample from the Polish population.

Results. We found no significant differences of FCRL3 −169T>C genotypes and alleles between patients with SLE and healthy individuals. However, in the dominant model we found a significant association between the FCRL3 −169T>C polymorphism and the presence of anti-Scl-70 antibody (Ab) [OR = 4.747 (95 % CI = 1.639–13.749), p = 0.0011, p corr = 0.0198]. Moreover, in the dominant model we observed a significant contribution of FCRL3 −169T>C to the presence of either anti-La or anti-Scl-70 Abs [OR = 4.378 (95 % CI = 1.793–10.690, p = 0.0003, p corr = 0.0054)].

Conclusions. Our study demonstrated that the FCRL3 −169T>C polymorphism is not a risk factor of SLE in the Polish population, but this polymorphism may contribute to autoantibody production in this disease.

Acknowledgements

Supported by Grant No 502-01-01124182-07474, Poznań University of Medical Sciences. The technical assistance of Ms. Alicja Pinczewska is gratefully acknowledged.

Conflict of interest

None.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.